Finance

Beta
Lists
JBIO:NASDAQ
Jade Biosciences Inc
$21.51
-1.38%
(-0.30) 1D
$21.51
0.00% (0.00)
After hours
Closed: Jul 2, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for JBIO...
Open
$22.03
High
$22.03
Low
$20.20
Mkt. cap
1.28B
Avg. vol.
1.36M
Volume
1.20M
52-wk high
$27.96
52-wk low
$6.67
EPS
-$2.41
Beta
1.43
Shares outstanding
60.86M
No. of employees
55
Open
$22.03
High
$22.03
Low
$20.20
Mkt. cap
1.28B
Avg. vol.
1.36M
Volume
1.20M
52-wk high
$27.96
52-wk low
$6.67
EPS
-$2.41
Beta
1.43
Shares outstanding
60.86M
No. of employees
55
News stories
From sources across the web
About Jade Biosciences Inc
CEO-
Employees55
Founded2024
HeadquartersWaltham, Massachusetts, United States
SectorBiotechnology
Websitejadebiosciences.com
Analyst ratings
Based on 10 analysts giving stock ratings to JBIO in the past 3 months
Strong buy
Buy
10
Hold
0
Sell
0
12-month forecast
Based on 10 Wall Street analysts offering 12 month price targets for JBIO in the last 3 months.
Highest
Current $21.51
$74.00 (+244.03%)
Average
$48.50 (+125.48%)
Lowest
$40.00 (+85.96%)
Analyst
Recommendation
Action
Price target
Projected
Date
Michael Yee
UBS
Buy
Initiated
$45.00
+109.2%
06/15/2026
Rami Katkhuda
LifeSci Capital
Buy
Maintained
$42.00
+95.3%
06/06/2026
Laura Chico
Wedbush
Buy
Maintained
$45.00
+109.2%
06/02/2026
Vamil Divan
Guggenheim
Buy
Reiterated
$47.00
+118.5%
06/01/2026
Julian Harrison
BTIG
Buy
Maintained
$74.00
+244%
06/01/2026
Akash Tewari
Jefferies
Buy
Maintained
$40.00
+86%
06/01/2026
Matt Phipps
William Blair
Buy
Maintained
-
-
06/01/2026
Arthur He CFA
H.C. Wainwright
Buy
Reiterated
$55.00
+155.7%
06/01/2026
Tyler Van Buren
TD Cowen
Buy
Maintained
-
-
05/08/2026
Alex Thompson CFA
Stifel Nicolaus
Buy
Maintained
$40.00
+86%
05/07/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
22.55M
22.01M
28.54M
36.05M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5.23M
5.39M
6.44M
7.39M
Operating expense
27.78M
27.40M
34.98M
43.44M
Total operating expenses
27.78M
27.40M
34.98M
43.44M
Operating income
-27.78M
-27.40M
-34.98M
-43.44M
Other non operating income
-
-28.00K
20.00K
-9.00K
EBT including unusual items
-32.13M
-25.18M
-31.87M
-40.35M
EBT excluding unusual items
-25.95M
-25.18M
-31.87M
-40.35M
Income tax expense
-
-
58.00K
16.00K
Effective tax rate
-
-
-0.18%
-0.04%
Other operating expenses
-
-
-
-
Net income
-32.13M
-25.18M
-31.93M
-40.37M
Net profit margin
-
-
-
-
Earnings per share
-
-
-
-
Interest and investment income
1.83M
2.25M
3.08M
3.10M
Interest expense
-
-
-
-
Net interest expenses
1.83M
2.25M
3.08M
3.10M
Depreciation and amortization charges
-
-
-
-
EBITDA
-27.78M
-27.39M
-34.97M
-43.44M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer